These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16556667)

  • 1. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
    Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
    Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.
    Nykjaer KM; Grønbaek H; Nielsen DT; Christiansen P; Astrup LB
    In Vivo; 2007; 21(4):679-84. PubMed ID: 17708366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
    van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
    Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.
    Stronge RL; Turner GB; Johnston BT; McCance DR; McGinty A; Patterson CC; Ardill JE
    Ann Clin Biochem; 2008 Nov; 45(Pt 6):560-6. PubMed ID: 18782815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.
    Hellman P; Lundström T; Ohrvall U; Eriksson B; Skogseid B; Oberg K; Tiensuu Janson E; Akerström G
    World J Surg; 2002 Aug; 26(8):991-7. PubMed ID: 12016480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome.
    Swärd C; Johanson V; Nieveen van Dijkum E; Jansson S; Nilsson O; Wängberg B; Ahlman H; Kölby L
    Br J Surg; 2009 May; 96(5):517-21. PubMed ID: 19358175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).
    de Herder WW
    Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
    Igaz P; Rácz K; Tulassay Z
    Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical diagnosis of neuroendocrine GEP tumor.
    Oberg K
    Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung.
    García-Yuste M; Matilla JM; Cueto A; Paniagua JM; Ramos G; Cañizares MA; Muguruza I;
    Eur J Cardiothorac Surg; 2007 Feb; 31(2):192-7. PubMed ID: 17196822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of midgut carcinoids.
    Akerström G; Hellman P; Hessman O; Osmak L
    J Surg Oncol; 2005 Mar; 89(3):161-9. PubMed ID: 15719373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
    Cunningham JL; Grimelius L; Sundin A; Agarwal S; Janson ET
    Acta Oncol; 2007; 46(6):747-56. PubMed ID: 17653896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic carcinoid tumor: changing patterns of care over two decades.
    Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
    J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary atypical carcinoid: predictors of survival in 106 cases.
    Beasley MB; Thunnissen FB; Brambilla E; Hasleton P; Steele R; Hammar SP; Colby TV; Sheppard M; Shimosato Y; Koss MN; Falk R; Travis WD
    Hum Pathol; 2000 Oct; 31(10):1255-65. PubMed ID: 11070119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin.
    Johanson V; Tisell LE; Olbe L; Wängberg B; Nilsson O; Ahlman H
    Br J Cancer; 1999 Jun; 80(8):1259-61. PubMed ID: 10376980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.
    Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA
    Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.